188 related articles for article (PubMed ID: 34597727)
21. Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing.
Modi ME; Majchrzak MJ; Fonseca KR; Doran A; Osgood S; Vanase-Frawley M; Feyfant E; McInnes H; Darvari R; Buhl DL; Kablaoui NM
J Pharmacol Exp Ther; 2016 Aug; 358(2):164-72. PubMed ID: 27217590
[TBL] [Abstract][Full Text] [Related]
22. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
23. Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model.
Quintana DS; Alvares GA; Hickie IB; Guastella AJ
Neurosci Biobehav Rev; 2015 Feb; 49():182-92. PubMed ID: 25526824
[TBL] [Abstract][Full Text] [Related]
24. Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques.
Freeman SM; Samineni S; Allen PC; Stockinger D; Bales KL; Hwa GG; Roberts JA
Psychoneuroendocrinology; 2016 Apr; 66():185-94. PubMed ID: 26826355
[TBL] [Abstract][Full Text] [Related]
25. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
26. Statistical and Methodological Considerations for the Interpretation of Intranasal Oxytocin Studies.
Walum H; Waldman ID; Young LJ
Biol Psychiatry; 2016 Feb; 79(3):251-7. PubMed ID: 26210057
[TBL] [Abstract][Full Text] [Related]
27. Lipo-oxytocin-1, a Novel Oxytocin Analog Conjugated with Two Palmitoyl Groups, Has Long-Lasting Effects on Anxiety-Related Behavior and Social Avoidance in CD157 Knockout Mice.
Mizuno A; Cherepanov SM; Kikuchi Y; Fakhrul AA; Akther S; Deguchi K; Yoshihara T; Ishihara K; Shuto S; Higashida H
Brain Sci; 2015 Jan; 5(1):3-13. PubMed ID: 25612002
[TBL] [Abstract][Full Text] [Related]
28. Intranasal Neuropeptide Administration To Target the Human Brain in Health and Disease.
Spetter MS; Hallschmid M
Mol Pharm; 2015 Aug; 12(8):2767-80. PubMed ID: 25880274
[TBL] [Abstract][Full Text] [Related]
29. Oxytocin and vasopressin flatten dominance hierarchy and enhance behavioral synchrony in part via anterior cingulate cortex.
Jiang Y; Platt ML
Sci Rep; 2018 May; 8(1):8201. PubMed ID: 29844336
[TBL] [Abstract][Full Text] [Related]
30. Oxytocin: a therapeutic target for mental disorders.
Matsuzaki M; Matsushita H; Tomizawa K; Matsui H
J Physiol Sci; 2012 Nov; 62(6):441-4. PubMed ID: 23007624
[TBL] [Abstract][Full Text] [Related]
31. Brain uptake and the analgesic effect of oxytocin--its usefulness as an analgesic agent.
Kang YS; Park JH
Arch Pharm Res; 2000 Aug; 23(4):391-5. PubMed ID: 10976589
[TBL] [Abstract][Full Text] [Related]
32. Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice.
Cherepanov SM; Yokoyama S; Mizuno A; Ichinose W; Lopatina O; Shabalova AA; Salmina AB; Yamamoto Y; Okamoto H; Shuto S; Higashida H
Pharmacol Res Perspect; 2017 Feb; 5(1):e00290. PubMed ID: 28596839
[TBL] [Abstract][Full Text] [Related]
33. The impact of oxytocin administration on brain activity: a systematic review and meta-analysis protocol.
Quintana DS; Outhred T; Westlye LT; Malhi GS; Andreassen OA
Syst Rev; 2016 Nov; 5(1):205. PubMed ID: 27899138
[TBL] [Abstract][Full Text] [Related]
34. Intranasal delivery: circumventing the iron curtain to treat neurological disorders.
Jiang Y; Li Y; Liu X
Expert Opin Drug Deliv; 2015; 12(11):1717-25. PubMed ID: 26206202
[TBL] [Abstract][Full Text] [Related]
35. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys.
Parker KJ; Buckmaster CL; Schatzberg AF; Lyons DM
Psychoneuroendocrinology; 2005 Oct; 30(9):924-9. PubMed ID: 15946803
[TBL] [Abstract][Full Text] [Related]
36. Consistency and efficacy of two methods of intranasal oxytocin application in dogs.
Schaebs FS; Deschner T; Range F; Karl S; Marshall-Pescini S
Domest Anim Endocrinol; 2020 Jul; 72():106436. PubMed ID: 32114215
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin.
Zaman RU; Mulla NS; Braz Gomes K; D'Souza C; Murnane KS; D'Souza MJ
Int J Pharm; 2018 Sep; 548(1):698-706. PubMed ID: 30031864
[TBL] [Abstract][Full Text] [Related]
38. Within vs. between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions.
Chen X; Gautam P; Haroon E; Rilling JK
Psychoneuroendocrinology; 2017 Apr; 78():22-30. PubMed ID: 28142074
[TBL] [Abstract][Full Text] [Related]
39. Current Nanoparticle Approaches in Nose to Brain Drug Delivery and Anticancer Therapy - A Review.
Ansari MA; Chung IM; Rajakumar G; Alzohairy MA; Alomary MN; Thiruvengadam M; Pottoo FH; Ahmad N
Curr Pharm Des; 2020; 26(11):1128-1137. PubMed ID: 31951165
[TBL] [Abstract][Full Text] [Related]
40. Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles.
Bales KL; Perkeybile AM; Conley OG; Lee MH; Guoynes CD; Downing GM; Yun CR; Solomon M; Jacob S; Mendoza SP
Biol Psychiatry; 2013 Aug; 74(3):180-8. PubMed ID: 23079235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
